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ABSTRACT
The prevalence of heart failure (HF) is on the rise due to the aging of society. Furthermore, 
the continuous progress and widespread adoption of screening and diagnostic strategies 
have led to an increase in the detection rate of HF, effectively increasing the number of 
patients requiring monitoring and treatment. Because HF is associated with substantial rates 
of mortality and morbidity, as well as high socioeconomic burden, there is an increasing 
need for developing specific guidelines for HF management. The Korean guidelines for the 
diagnosis and management of chronic heart failure (CHF) were introduced in March 2016. 
However, CHF and acute heart failure (AHF) represent distinct disease entities. Here, we 
introduce the Korean guidelines for the management of AHF with reduced or preserved 
ejection fraction. Part III of this guideline covers management strategies optimized according 
to the etiology of AHF and the presence of co-morbidities.
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INTRODUCTION
The number of patients with heart failure (HF) has been on the rise as a consequence of the 
aging of society and the improvement in screening and diagnostic techniques. Therefore, 
there is an increasing need for developing guidelines for the diagnosis and treatment of 
Korean Circ J. 2019 Jan;49(1):46-68
https://doi.org/10.4070/kcj.2018.0351
pISSN 1738-5520·eISSN 1738-5555
Review Article
Received: Oct 4, 2018
Revised: Dec 14, 2018
Accepted: Dec 18, 2018
Correspondence to
Hyun-Jai Cho, MD
Division of Cardiology, Department of Internal 
Medicine, Seoul National University Hospital, 
101, Daehak-ro, Jongno-gu, Seoul 03080, 
Korea.
E-mail: hyunjaicho@snu.ac.kr
*Min-Seok Kim and Ju-Hee Lee contributed 
equally to this work.
Copyright © 2019. The Korean Society of 
Cardiology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted noncommercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Min-Seok Kim 
https://orcid.org/0000-0002-8512-797X
Ju-Hee Lee 
https://orcid.org/0000-0002-0858-0973
Hyun-Jai Cho 
https://orcid.org/0000-0002-2779-4037
Jae Yeong Cho 
https://orcid.org/0000-0002-9393-2821
Jin-Oh Choi 
https://orcid.org/0000-0002-2441-2267
Min-Seok Kim , MD1,*, Ju-Hee Lee , MD2,*, Hyun-Jai Cho , MD3,  
Jae Yeong Cho , MD4, Jin-Oh Choi , MD5, Kyung Kuk Hwang , MD2,  
Byung Su Yoo , MD6, Seok-Min Kang , MD7, and Dong-Ju Choi , MD8
1 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, 
Chungbuk National University College of Medicine, Cheongju, Korea
3Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
4Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea
5 Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University 
School of Medicine, Seoul, Korea
6 Division of Cardiology, Department of Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
7Division of Cardiology, Department of Medicine, Yonsei University College of Medicine, Seoul, Korea
8 Department of Internal Medicine, Cardiovascular Center, Seoul National University Bundang Hospital, 
Seongnam, Korea
KSHF Guidelines for the Management 
of Acute Heart Failure: Part III. 
Specific Management of Acute Heart 
Failure According to the Etiology and 
Co-morbidity
Kyung Kuk Hwang 
https://orcid.org/0000-0003-3464-3023
Byung Su Yoo 
https://orcid.org/0000-0002-3395-4279
Seok-Min Kang 
https://orcid.org/0000-0001-9856-9227
Dong-Ju Choi 
https://orcid.org/0000-0003-0146-2189
Conflict of Interest
The authors have no financial conflicts of 
interest.
Author Contributions
Conceptualization: Kim MS, Lee JH, Cho HJ, 
Cho JY, Choi JO, Hwang KK, Yoo BS, Kang SM, 
Choi DJ; Data curation: Kim MS, Lee JH, Cho 
HJ, Cho JY, Choi JO, Hwang KK, Yoo BS, Kang 
SM, Choi DJ; Supervision: Cho HJ, Yoo BS, 
Kang SM, Choi DJ; Writing - original draft: Kim 
MS, Lee JH, Cho HJ, Cho JY, Choi JO, Hwang 
KK, Yoo BS; Writing - review & editing: Kim MS, 
Lee JH.
HF. Although guidelines for HF management have already been issued by American and 
European associations, many aspects of such guidelines do not reflect the domestic reality 
in Korea due to the social and anthropological characteristics of the Korean population. 
Thus, to help clinicians establish the best treatment plan for Korean patients with HF, it is 
necessary to develop specific guidelines that reflect the clinical situation in Korea. In 2012, 
the Korean Society of Heart Failure (KSHF) established the Guideline Writing Committee 
to develop the treatment guidelines for HF. The Korean guidelines for the diagnosis and 
management of chronic heart failure (CHF) were introduced in March 2016.1) However, CHF 
and acute heart failure (AHF) are distinct disease entities, warranting different approaches 
for diagnosis and treatment. Here, we introduce the Korean guidelines for the management 
of AHF with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively). In Part 
III of this guideline, we discuss management strategies optimized according to the etiology 
of AHF and the presence of co-morbidities.
This guideline was developed based on previously issued international guidelines and 
amended to reflect the clinical situation in Korea. A committee of KSHF members decided 
on the format of the guideline, the selection of topics addressed, and the composition of 
the Writing Committee. To develop the guidelines, we considered all clinical studies and 
evidence included in the international guidelines, as well as domestic research conducted 
in Korean patients with HF. Members of the Writing Committee first drafted thematic 
manuscripts, which were then assembled and arranged according to the evidence-
based scales. To ensure transparency and facilitate future revision of the guidelines, we 
documented the process followed for issuing a recommendation for each topic based on 
the gathered evidence. The guideline was drafted, reviewed by the advisory committee, 
and finalized after receiving endorsement from the Korean Society of Cardiology, Korean 
Society of Hypertension, Korean Society of Interventional Cardiology, Korean Society of 
Echocardiography, and Korean Society of Lipid and Atherosclerosis. While working on this 
guideline, the members of the Writing Committee were not affected by external influences 
and made every effort to exclude conflicts of interests.
The Writing Committee issued the level of recommendation upon a comprehensive 
analysis of evidence from studies describing real clinical experience, from surveys, from 
epidemiologic, observational, and randomized clinical studies, and from meta-analyses. The 
level of evidence and class of recommendation were defined so as to have a clear formulation, 
provide straightforward instructions, and be easily adopted in daily clinical practice 
(Supplementary Tables 1 and 2).
This guideline is intended to help improve clinical practice by providing recommendations 
based on clinical evidence. As such, the guideline does not serve as a basis for clinical 
judgement. The final decision in the treatment of each patient should be made by the treating 
physician according to their personal opinion and judgment, while using the guideline to 
support these decisions.
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ISCHEMIC HEART DISEASE/ACUTE CORONARY 
SYNDROME
To reduce cardiomyocyte necrosis and early mortality, primary percutaneous coronary 
intervention must be performed promptly patients with acute coronary syndrome and ST-
segment elevation or new left bundle branch block.2-7) If percutaneous coronary intervention 
or coronary artery bypass grafting cannot be performed, intravenous thrombolytic therapy 
must be administered.8) If symptoms develop within 12–24 hours or signs of congestive HF, 
hemodynamic instability, or persistent ischemia is detected, it is appropriate to conduct 
primary percutaneous coronary intervention.8-10) If patients who experienced serious 
HF-associated symptoms, cardiogenic shock, or hemodynamically unstable ventricular 
arrhythmia did not receive primary percutaneous coronary intervention, coronary 
angiography to enable percutaneous coronary intervention must be performed immediately 
unless it is deemed unlikely to bring any benefits.11)12)
Despite the recent advances in medical treatment, patients with severe coronary artery 
disease and decreased left ventricular contractility typically have poor prognosis with 
drug treatment alone.13) Elective reperfusion therapy can increase the survival rate of such 
patients,14-22) whereas coronary artery bypass grafting can be considered in patients with 
ischemic heart disease and severe left ventricular dysfunction, where it is expected to increase 
survival regardless of myocardial variability.15)20)23-27)
Intravenous opioids can be used to alleviate symptoms and improve dyspnea in patients 
with ischemic chest pain. Routine injection of opioids is not recommended in AHF 
patients but can be used in patients with severe dyspnea. As opioids can hinder respiration, 
consciousness and breathing must be checked frequently.28)29)
HYPERTENSIVE EMERGENCY
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1.  In patients with ST-segment elevation or left bundle branch block, percutaneous coronary 
intervention or coronary artery bypass grafting must be performed to reduce cardiomyocyte 
necrosis and early mortality rates (class of recommendation I, level of evidence A).
2.  If percutaneous coronary intervention and coronary artery bypass grafting are not suitable 
options for controlling ST-segment elevation or new left bundle branch block, intravenous 
thrombolytic therapy must be performed (class of recommendation I, level of evidence A).
3.  In hemodynamically unstable patients with non-ST elevation acute coronary syndrome, 
emergency reperfusion techniques such as percutaneous coronary intervention or coronary artery 
bypass grafting should be performed as early as possible (class of recommendation I, level of 
evidence A).
4.  Intravenous opioids can be considered in patients with ischemic chest pain to improve symptoms 
and dyspnea (class of recommendation IIb, level of evidence B).
1.  A rapid and excessive rise in blood pressure can cause AHF accompanied by pulmonary edema, 
and thus must be managed immediately with antihypertensive therapy (class of recommendation 
I, level of evidence C).
2.  Within the first few hours of AHF treatment, it is appropriate to use intravenous vasodilators and 
loop diuretics in combination with active antihypertensive therapy to lower blood pressure within 
25% of the initial value (class of recommendation IIa, level of evidence B).
Hypertensive emergency refers to a rapid rise in blood pressure (>180/120 mmHg) and 
progression of target organ damage.30) In patients with left ventricular failure accompanied by 
pulmonary edema, immediate hospital admission and prompt initiation of antihypertensive 
therapy are required.31)32) Organ damage can also occur if blood pressure rises quickly without 
exceeding 180/120 mmHg. However, excessive lowering of blood pressure can cause ischemia 
in the kidney, brain, and coronary arteries. Therefore, this process must be performed with 
caution to ensure that the extent of the blood pressure drop does not exceed 25% of the 
initial blood pressure in the first few hours.33-35) It is sensible to use aggressive therapy with 
combined vasodilator injection and loop diuretics. Vasodilator injection can be considered in 
patients with AHF, to alleviate symptoms and decrease congestion.34)36-38)
MYOCARDITIS
Myocarditis can have many etiologies. While viral infection is the most common etiology, 
systemic autoimmune diseases such as drug hypersensitivity, lupus erythematosus, or 
Churg-Strauss syndrome may also cause myocarditis. Endomyocardial biopsy is the standard 
method for diagnosing myocarditis. The findings of lymphocytic infiltration and heart 
muscle damage in the biopsy specimens are used to diagnose and classify myocarditis 
according to Dallas criteria.39) Moreover, endomyocardial biopsy can accurately differentiate 
specific myocarditis types such as giant-cell myocarditis or eosinophilic myocarditis, 
and helps in predicting patient prognosis. According to a small-scale research study on 
myocarditis, survival rate is lower in patients with inflammatory cell infiltration evident 
on immunohistochemical staining of endomyocardial biopsy specimens.40) With the 
development of cardiac MRI technology, diagnosing myocarditis noninvasively has recently 
become possible. Cardiac MRI is used to indirectly diagnose myocarditis by detecting early-
stage myocardial edema or inflammatory myocardial damage,41) so patients with suspected 
myocarditis must also have relevant clinical manifestations. However, this approach 
is limited because it may yield false negative results if there are no other indicators of 
myocarditis, such as in patients with giant-cell myocarditis or less-than-severe myocarditis.
Observational studies reported that immunoregulatory treatment (e.g., with 
immunosuppressants) may help control inflammation in patients with myocarditis. However, 
a larger randomized study reported that the clinical effects of immunosuppressive or 
immunoregulatory treatment were ambiguous or even harmful at times; therefore, routine 
immunosuppressive treatment is not recommended in patients with myocarditis.42)
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1.  In patients with myocarditis, endomyocardial biopsy can help diagnose and predict prognosis 
(class of recommendation IIa, level of evidence C).
2.  Cardiac magnetic resonance imaging (MRI) can be considered for diagnosing myocarditis (class 
of recommendation IIb, level of evidence B).
3.  In patients with myocarditis, routine immunosuppressive therapy not increase survival (class of 
recommendation III, level of evidence B).
4.  Patients with hemodynamically unstable fulminant myocarditis refractory to medication require 
mechanical circulatory support (class of recommendation I, level of evidence B).
3.  In AHF, vasodilator injection is appropriate as a primary treatment to alleviate symptoms and 
decrease congestion (class of recommendation IIa, level of evidence B).
Thus, in principle, myocarditis patients should receive the same treatment as that 
recommended in HF patients. However, if drug therapies cannot maintain adequate blood 
pressure in patients with hemodynamically unstable fulminant myocarditis patients, a 
mechanical cardiac support device (MCSD) must be used promptly. In patients who receive 
an MCSD and later have it removed as their health improves, the long-term survival is very 
high (>90% for 10 years after the onset of myocarditis).43)44)
Cardiac transplantation must be considered in myocarditis patients if HF does not improve 
with appropriate drug treatment or after insertion of an MCSD. Research revealed that 
the time from symptom onset to cardiogenic shock was shorter in patients who received 
an MCSD that was removed after recovery than in those who eventually needed cardiac 
transplantation.45) Therefore, cardiac transplantation can be seen as a treatment option better 
suited for chronic than for acute myocarditis. Recent studies reported that the survival rate 
of cardiac transplant recipients is similar to that of other HF patients.46)47) However, patients 
with sarcoidosis or giant-cell myocarditis have a risk of recurrence after cardiac transplant 
and thus should be monitored carefully.46)
VALVULAR HEART DISEASE
Valvular heart disease can act as both a cause and an aggravating factor of HF. For this reason, 
HF patients with valvular heart disease are categorized as high risk. After a complete medical 
examination, the treatment direction must be consulted and planned by a multidisciplinary 
team involving a valvular heart disease specialist, an HF specialist, a cardiac surgeon, a valve 
intervention specialist, a cardiovascular imaging specialist, and an anesthesiologist. All patients 
must receive the best drug treatment for HF, according to the guidelines. Patients with severe 
aortic valve stenosis may develop hypotension when taking vasodilators, so caution is needed.
Aortic valve stenosis
Aortic valve stenosis is a cause of HF, and its prevalence is increasing due to the aging of 
society. During the early stages of AHF caused by aortic valve stenosis, diuretic therapy can 
improve the patient's condition; however, unless systemic vascular circulation improves, 
poor prognosis is unavoidable. Aortic valve replacement surgery is a classic treatment for 
aortic valve stenosis. However, as the mean patient age increases together with the range 
of associated diseases, more and more patients are categorized as having high surgical risk 
and thus are poor candidates for aortic valve replacement surgery. Percutaneous aortic valve 
replacement was developed as a suitable intervention strategy in such high-risk patients, 
but no study to date has compared the outcomes of surgical and percutaneous aortic valve 
replacement in patients with aortic valve stenosis accompanied by AHF.
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1.  The prognosis of AHF caused by aortic valve stenosis can be improved more dramatically with 
percutaneous or surgical therapy than with symptomatic therapy (class of recommendation I, 
level of evidence A).
2.  If surgery is not possible in a patient with AHF caused by aortic valve stenosis, a more 
substantial improvement in prognosis can be achieved with percutaneous aortic valve 
replacement than with symptomatic therapy (class of recommendation I, level of evidence A).
3.  The prognosis of patients with AHF caused by mitral insufficiency can be improved more 
extensively by surgical therapy than by symptomatic therapy (class of recommendation I, level of 
evidence A).
Several randomized studies reported no difference between percutaneous aortic valve 
replacement and surgical therapy in terms of overall or cardiac mortality in patients with 
aortic valve stenosis.48-57) Compared to patients who received surgery, those who underwent 
percutaneous aortic valve replacement had lower incidence of hemorrhage and new-onset 
atrial fibrillation, but higher incidence of major cerebrovascular accidents and vascular 
complications. On the other hand, compared to patients who received medical treatment, 
those who underwent percutaneous aortic valve replacement had lower readmission 
rates, lower mortality rates, and higher survival rates but were at a high risk of major 
cerebrovascular accidents. A multidisciplinary approach involving a valve intervention 
specialist, cardiovascular imaging specialists, anesthesiologist, and cardiac surgeon is 
needed when determining the percutaneous aortic valve replacement indications of patients 
with aortic valve stenosis.
Aortic valve insufficiency
Aortic valvuloplasty or valve replacement can be performed in symptomatic patients with 
severe aortic valve insufficiency or left ventricular systolic dysfunction (left ventricular 
ejection fraction <50%), regardless of symptoms. However, there is currently no clear 
recommendation for the treatment of AHF accompanied with aortic insufficiency.
Mitral insufficiency
Mitral insufficiency is the most common valvular heart disease in patients with HFpEF or 
HFrEF, occurring secondary to morphological changes induced by HF-related hemodynamic 
changes. Mitral insufficiency accompanied by HF is usually not severe and can be improved 
if the disease responsible for the insufficiency is treated. However, different therapeutic 
approaches are needed depending on the type of mitral insufficiency (primary or secondary). 
Thoracotomy is generally used for treating primary mitral insufficiency, but percutaneous 
mitral valve intervention can be considered in patients who are not candidates for surgery 
due to high risk. In patients with mitral insufficiency, the 12-month and 2-year outcomes of 
percutaneous mitral valve intervention were similar to those of surgery.58-60) Percutaneous 
mitral valve intervention was associated with reduced need for transfusion and mechanical 
ventilation but increased need for reparative mitral valve surgery. However, there no 
randomized controlled studies have compared percutaneous mitral valve intervention and 
symptomatic therapy or surgical therapy plus symptomatic therapy. The study results of 
the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan 
(EVEREST) and EVEREST II trials revealed no difference between percutaneous mitral valve 
intervention and surgery regarding mortality or incidence of severe mitral insufficiency at 
30 days, 1 year, 2 years, and 4 years, respectively, although these conclusions may not be 
generalizable to all mitral insufficiency patients.
Tricuspid insufficiency
Secondary tricuspid insufficiency in relation to elevated right ventricular pressure and 
volume overload is frequently observed as a natural course of HF. Because severe tricuspid 
insufficiency worsens the symptoms and signs of right HF, diuretics are used to reduce 
peripheral edema. Passive hepatic congestion is frequently observed in these patients, and a 
high-dose aldosterone antagonist is used to improve such symptoms.61)62) When secondary 
tricuspid insufficiency is accompanied by HF, tricuspid insufficiency is alleviated through 
active HF treatment. The optimal surgical strategy in patients with secondary tricuspid 
insufficiency accompanied by HF has not been established, but surgical therapy is advised 
in patients with tricuspid insufficiency who needed mitral or aortic valve surgery. Currently, 
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percutaneous intervention is attempted in patients with tricuspid insufficiency, but there are 
no clear recommendations in patients with AHF accompanied with tricuspid insufficiency.
RIGHT HEART FAILURE
The pathophysiologic mechanisms underlying right ventricular dysfunction can be classified 
into 3 categories: decreased right ventricular contractility, right ventricular pressure overload, 
and right ventricular volume overload.63) If there is decreased right ventricular contractility 
(like in MI), right ventricular output is reduced, leading to decreased left ventricular preload 
and, consequently, reduced left ventricular output.64) The right ventricular pressure and 
volume overload observed in acute pulmonary artery embolism causes right ventricular 
enlargement and creates a leftward shift of the interventricular septum, decreased left 
ventricular preload, and reduced left ventricular output resulting in hypotension.65) Moreover, 
due to right ventricular pressure overload, the right ventricular wall tension increases, 
thereby increasing the oxygen demand of the right ventricular myocardium. Hypotension and 
increased wall tension of the right ventricle causes reduced left ventricular output, decreasing 
right coronary artery flow. This forms a vicious cycle, creating an environment that facilitates 
the development of right ventricular ischemia.66)
Since the right ventricle has good recovery, its functions can be regained if right HF is treated 
early. Thus, the treatment for right HF and the treatment for the causes of right HF must go 
hand in hand. Right heart function is determined by preload (volume status), contractility, 
and afterload, so controlling these 3 parts can improve the symptoms and signs of HF.
Right ventricular myocardial infarction
Right coronary artery occlusion causes right ventricular ischemia, but the right ventricle 
has a lower oxygen demand67) and its blood supply flows during both systole and diastole.68) 
A collateral circulation develops from the left coronary artery,69) which can help avoid right 
ventricular MI even in patients with long-term ischemia.70) True right ventricular MI is very 
rare.71) Therefore, the treatment guidelines for right ventricular MI are identical to those of 
left ventricular MI.72)73)
Pulmonary embolism
The increase in afterload induced by acute pulmonary embolism can cause right HF.74-76) If the 
patient’s vital signs are stable, anticoagulants such as heparin or a new oral anticoagulant 
(non-vitamin K oral anticoagulant) can improve symptoms; however, if the patient is 
hemodynamically unstable (e.g., experiencing hypoxia), thrombolytics must be administered 
and embolectomy must be performed.77) The use of thrombolytics was shown to improve 
prognosis in moderate risk patients with acute pulmonary embolism with stable vital signs 
but with signs of right HF on echocardiography.78)
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1.  Coronary reperfusion must be performed in patients with right ventricular myocardial infarction 
(MI) accompanied by ST-segment elevation acute MI (class of recommendation I, level of 
evidence A).
2.  Use of thrombolytics is appropriate in patients with acute right HF due to pulmonary embolism 
(class of recommendation IIa, level of evidence B).
3.  MCSD use can be very helpful in patients with right HF and cardiogenic shock refractory to 
medication (class of recommendation IIa, level of evidence C).
Clinical role of mechanical cardiac support in acute right heart failure
The advantage of mechanical cardiac support is that it decreases the myocardial oxygen 
demand while maintaining or increasing blood flow, without causing myocardial ischemia.79) 
The use of an intra-aortic balloon pump can improve right heart function by decreasing 
left ventricular filling pressure and right ventricular afterload. Veno-arterial extracorporeal 
membrane oxygenation bypasses the right heart and pulmonary circulation and can be used 
as a temporary treatment for right HF until heart function is recovered.80-82)
CARDIORENAL SYNDROME
Because the heart and kidneys interact hemodynamically and neurohormonally, acute or 
chronic disease in 1 organ can induce acute or chronic dysfunction of the other organ. This 
phenomenon is referred to as the cardiorenal syndrome and can be classified into 5 types 
according to disease progression (acute or chronic) and according to the culprit organ (heart 
or kidneys): type 1, abrupt worsening of heart function inducing acute kidney injury; type 
2, chronic abnormalities in heart function inducing chronic kidney disease; type 3, abrupt 
worsening of kidney function inducing acute cardiac disorder; type 4, chronic kidney disease 
contributing to decreased cardiac function; and type 5, acute or chronic systemic condition 
inducing heart and kidney dysfunction.83) AHF patients have type 1 cardiorenal syndrome.
An estimated 30–60% of HF patients experience a greater-than-moderate degree of renal 
dysfunction,84)85) and it has been reported that 20–30% of patients undergoing AHF treatment 
experience renal function deterioration.86-89) Among Korean patients hospitalized with AHF, 
14.9% have serum creatinine levels >2.0 mg/dL.90) Both underlying renal dysfunction and renal 
function deterioration during treatment have a negative prognostic effect in HF patients.84-86)90)91)
Some studies reported improved renal function after use of a left ventricular assist device and 
cardiac resynchronization therapy, implying that cardiorenal syndrome is partially reversible.92)93) 
However, decreased renal function can be an indicator of severe HF. In this case, solely improving 
renal function might not improve prognosis. No medication available to date is known to directly 
improve the renal function of HF patients. If there are signs of elevated jugular venous pressure or 
evidence of congestion such as peripheral edema, the use of diuretics must be continued despite 
elevated blood urea nitrogen or serum creatinine levels. The effects of diuretics on renal function 
might vary. In some patients, renal function can deteriorate due to decreased renal perfusion 
caused by decreased ventricular filling pressure.94) Nevertheless, most patients with HF on the 
plateau of the Frank Starling curve would not experience renal function deterioration because 
changes in ventricular filling pressure would not have much effect on cardiac output,95) or would 
experience decreased renal venous pressure and intraperitoneal pressure, which would lead to 
right ventricular enlargement and improved renal function.96)97) Although diuretic therapy was 
correlated with renal function deterioration in the Evaluation Study of Congestive Heart Failure 
and Pulmonary Artery Catheterization Effectiveness (ESCAPE) study98) and in the EVEREST 
study,99) the death rate was lower in the group that received active diuretic therapy.
Although no clinical research on renin-angiotensin-aldosterone antagonists has focused 
on patients with cardiorenal syndrome, subgroup analyses and cohort studies showed that 
the long-term use of renin-angiotensin-aldosterone antagonists had positive prognostic 
effects even in patients with decreased renal function.100-103) Although partial aggravation 
of renal function may occur in the early phase of renin-angiotensin-aldosterone antagonist 
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administration, long-term prognosis was better in groups that received high doses.104-106) 
However, if decreased renal function is also present, there is a high possibility that side 
effects such as hyperkalemia or deteriorated renal function would occur.
The use of vasodilators has no clear advantage in patients with cardiorenal syndrome. In the 
Acute Decompensated Heart Failure National Registry (ADHERE) study, the patients who took 
combination therapy with diuretics and nitroglycerin or nesiritide experienced renal function 
deterioration more frequently than noted among those who took only diuretics.107) The Acute 
Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) 
and Renal Optimization Strategies Evaluation (ROSE) studies showed that nesiritide had 
no effect on renal function.108)109) In the Dopamine in Acute Decompensated Heart Failure 
(DAD-HF) and ROSE studies of dopamine, the use of inotripic agents had no effect on renal 
function,109)110) while the effect of inotropic agents on cardiorenal syndrome was unclear.
Ultrafiltration can be used in patients with deteriorated renal function and diuretic 
resistance. In the Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized for 
Acute Decompensated (UNLOAD) study111) and the Relief for Acutely Fluid-Overloaded 
Patients with Decompensated Congestive Heart Failure (RAPID-CHF) study,112) ultrafiltration 
resulted in greater loss of fluids but did not affect serum creatinine levels. In the Cardiorenal 
Rescue Study in Acute Decompensated Heart Failure (CARESS-HF) study,113) which 
targeted HF patients with gradually deteriorating renal function and persistent congestion, 
ultrafiltration resulted in similar weight loss but increased the serum creatinine levels and 
the risk of side effects. Thus, although ultrafiltration can help decrease fluid overload in some 
patients with diuretic resistance, it cannot be considered a primary treatment for AHF or an 
effective solution for cardiorenal syndrome.
STRESS-INDUCED CARDIOMYOPATHY
In 1990, the first case was reported of a patient who had symptoms and signs very similar 
to acute coronary syndrome but showed no meaningful stenosis or spasm of the coronary 
artery. Since then, there have been many reports of patients with an abnormal wall motion 
of the left ventricular apex related to physical and mental stress causing pathognomonic 
wall motion abnormalities of apical ballooning and left ventricular dysfunction. This was 
originally called Takotsubo cardiomyopathy because the affected left ventricle resembled the 
pot used to caught octopuses, but was later renamed stress-induced cardiomyopathy and 
categorized as a subgroup of acquired cardiomyopathy.114-120) Stress-induced cardiomyopathy 
frequently occurs in aged women after mental and physical stress. Stress-induced 
cardiomyopathy occurs in 1–2% of patients with suspected acute coronary syndrome and 
is known to accompany AHF in 45% of all cases.114-120) According to numerous domestic 
single-center studies, stress-induced cardiomyopathy occurs in 28% of intensive care unit 
patients.121)122) Although the causes of stress-induced cardiomyopathy are not yet clear, the 
presence of a preceding stressful condition is a known characteristic.123) Triggers generally 
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1.  Transthoracic echocardiography and coronary angiography or coronary computed tomography 
angiography must be used to diagnose stress-induced cardiomyopathy (class of recommendation 
I, level of evidence C).
2.  In patients with stress-induced cardiomyopathy, it is appropriate to also treat underlying diseases 
when treating AHF (class of recommendation IIa, level of evidence C).
include emotional factors (30%), physical factors (40%), and unclassified factors (30%). 
Recent studies report an increasing prevalence of stress-induced cardiomyopathy due to 
physical stress.123-125) Mechanisms proposed to underlie stress-induced cardiomyopathy 
include coronary artery vasoconstriction, microcirculatory disturbances, left ventricular 
outflow obstruction, catecholamine-induced myocardial stunning, hormonal interactions, 
and inflammation.123)124)
The modified Mayo Clinic diagnostic criteria are used to diagnose stress-induced 
cardiomyopathy:126) transient localized wall motion abnormality in the left mid-ventricular to 
apical area; new changes on electrocardiography, including ST-segment elevation or T-wave 
inversion, coupled with changes in the levels of cardiac enzymes; no evidence of significant 
coronary stenosis or acute rupture of the atherosclerotic plaque; exclusion of acute 
myocarditis and pheochromocytoma. To diagnose stress-induced cardiomyopathy, coronary 
artery disease must be excluded by confirming that there is no significant coronary stenosis 
or rupture of the atherosclerotic plaque on coronary angiography. Furthermore, as vasospasm 
cannot be excluded on angiography alone in the absence of significant coronary stenosis, a 
provocative vasospasm test could be considered if the patient is stable. Coronary angiography 
is required for making the definite diagnosis of stress-induced cardiomyopathy, but if 
invasive coronary angiography cannot be carried out, coronary artery disease can be ruled 
out through cardiac computed tomography. Performing echocardiography multiple times to 
monitor localized wall motion abnormalities can help with the diagnosis, and a nuclear scan 
can also be considered.126-128)
Since there are currently no specialized treatment guidelines for stress-induced 
cardiomyopathy, the treatment for HF and its causative diseases is implemented based 
on general AHF treatment guidelines.116)119)129-131) In patients with congestion, diuretics can 
be administrated if blood pressure is stable. Until left ventricular function is recovered, 
an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker can be 
administered. If the patient is hemodynamically unstable, an inotrope injection may be 
needed.129) The most common complication of stress-induced cardiomyopathy is AHF, 
as 15–50% of patients show symptoms and signs of HF.119) Cardiogenic shock (9.3%), 
pulmonary edema (25%), and life-threatening arrhythmias (4.2%) can occur as comorbid 
conditions. Mitral insufficiency, pericardial effusion, and dynamic left ventricular outflow 
tract obstruction can occur as well. Left ventricular apical thrombus formation can cause 
thromboembolism.132)
Stress-induced cardiomyopathy tends to improve after a few weeks. Localized wall 
motion abnormalities improve within 4–8 weeks, so if they are persistently observed on 
echocardiography, the condition must be re-evaluated for the possibility of a different 
diagnosis.116)120) The in-hospital mortality rate of stress-induced cardiomyopathy is 1–2%, but 
some high-risk groups have a death rate of up to 16%. Thus, if the severity of the underlying 
disease is high or stress-induced cardiomyopathy negatively affects the progress of HF, 
the prognosis is poor.133)134) On long-term follow-up, the recurrence rate of stress-induced 
cardiomyopathy is 2–10%.116)120)
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TACHYCARDIA-INDUCED CARDIOMYOPATHY
Tachycardia-induced cardiomyopathy is a type of HF caused by increased heart rate leading to left 
ventricular dysfunction.135) Because left ventricular dysfunction is proportional to tachycardia rate 
and duration, the systolic dysfunction can be partially or completely normalized by controlling 
the heart rate. Left ventricular dysfunction can occur in supraventricular tachycardia, ventricular 
tachycardia, or even frequent premature ventricular contractions.136) If tachycardia continues, 
it can cause atrio-ventricular dysynchrony, decreased myocardial contractility, elevated left 
ventricular filling pressure, reduced cardiac output, increased systemic vascular resistance, 
increased left ventricular wall stress, left ventricular enlargement, mitral insufficiency, and 
activation of the renin-angiotensin-aldosterone system and sympathetic nervous system,135)137)138) 
which induces ventricular remodeling. This not only results in cellular structure changes but also 
in the depletion of stored energy, increased oxidative stress, and impaired calcium signaling.
Tachycardia-induced cardiomyopathy can be suspected if a patient with idiopathic HF has 
persistent tachycardia. However, it is difficult to determine whether tachycardia is the cause 
or effect of HF. Thus, it is difficult to differentiate tachycardia-induced cardiomyopathy from 
general cardiomyopathy. Tachycardia-induced cardiomyopathy is easier to diagnose if ventricular 
function is recovered after the restoration of sinus rhythm or control of ventricular rate.
The key principles when treating tachycardia-induced cardiomyopathy are maintaining sinus 
rhythm and controlling ventricular rate,139) which helps improve left ventricular function, 
relieve symptoms, and prevent arrhythmia recurrence.135) Atrial fibrillation is the most 
common arrhythmia accompanied by HF, while tachycardia-induced cardiomyopathy can 
occur if the pulse exceeds 150 beats/min.61) It is appropriate for atrial fibrillation patients who 
also experience HF to maintain a ventricular rate of 60–100 beats/min. It was suggested in 
numerous treatment guidelines that controlling atrial fibrillation is not superior to restoring 
sinus rhythm,140)141) but this view cannot necessarily be applied to tachycardia-induced 
cardiomyopathy caused by atrial fibrillation.135)137) Studies conducted in patients with left 
ventricular failure accompanied by atrial fibrillation have found that, compared to heart rate 
control, the restoration of sinus rhythm provides better outcomes in terms of improving left 
ventricular function and quality of life.142)143) Therefore, restoring the sinus rhythm can be 
considered in patients with tachycardia-induced cardiomyopathy caused by atrial fibrillation. 
Methods of achieving sinus rhythm restoration include drug treatment, cardioversion, and 
catheter ablation. Amiodarone is the most effective drug for maintaining sinus rhythm.144) 
Dronedarone is dangerous to AHF patients and its use is not recommended.145) Catheter 
ablation can be considered as a suitable treatment method for restoring sinus rhythm in 
patients with HF accompanied by atrial fibrillation, providing increased left ventricular 
ejection fraction and improved symptoms.142)146)147)
Tachycardia-induced cardiomyopathy is known to occur in 6–10% of patients with 
supraventricular tachycardia,148)149) while left ventricular ejection fraction is known to 
improve after catheter ablation.148)150)151) Ventricular tachycardia or excessive premature 
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1.  It is appropriate to control heart rate or restore sinus rhythm as a treatment for tachycardia-
induced cardiomyopathy due to atrial fibrillation (class of recommendation IIa, level of evidence B).
2.  Catheter ablation to restore sinus rhythm can be considered for patients with symptomatic 
tachycardia-induced cardiomyopathy due to atrial fibrillation that is refractory to medication 
(class of recommendation IIb, level of evidence B).
ventricular contraction can cause tachycardia-induced cardiomyopathy via ventricular 
desynchronization.152) Although there are many definitions of excessive premature ventricular 
contraction, the occurrence of cardiomyopathy is increased when there are more than 10,000 
premature ventricular contractions or more than 24–26% of frequencies over the course of 24 
hours.135)153)154) A beta-blocker is the first-line agent, while amiodarone, sotalol, and dofetilide 
can also be used.135)137) Catheter ablation can be considered for treating premature ventricular 
contraction, with success rates of 70–90%155) and with improvements in left ventricular 
ejection fraction and general symptoms.156) In case reports and small observational studies, 
tachycardia-induced cardiomyopathy improved after catheter ablation even in patients with 
ventricular tachycardia.137)
PERIPARTUM CARDIOMYOPATHY
Peripartum cardiomyopathy occurs in pregnant woman between the last month of pregnancy 
and until up to 6 months postpartum, with no discernable cause. Peripartum cardiomyopathy 
occurs in one of every 1,300–1,400 pregnant women and, although the occurrence rate is low, 
the rates of heart transplant and death are high.157) Risk factors of peripartum cardiomyopathy 
include advanced maternal age, multifetal gestation, multipara status, pregnancy-induced 
hypertension, and long-term use of tocolytics.158)159) While the etiology remains unknown, 
peripartum cardiomyopathy is considered to arise from immunologic or pregnancy-related 
hemodynamic causes.160) Treatment for peripartum cardiomyopathy is quite similar to 
treatments for other types of HF61)136); however, but due to the risk of embryotoxicity, 
angiotensin-converting enzyme inhibitors and angiotensin receptor blockers cannot be 
used.161)162) Instead, hydralazine and nitrates can be used relatively safely, even during 
pregnancy.163) One study reported improved ventricular contractility following bromocriptine 
administration, based on which the recommended dose is 2.5 mg twice daily for 2 weeks.164)
A pregnant woman with suspected peripartum cardiomyopathy should be referred 
to a cardiologist and obstetrician. HF drugs must be administered carefully because 
they can affect the fetus; hence, fetal development must be closely monitored. The 
optimal delivery method and timing have not been established. If the conditions of the 
mother and the baby do not worsen, preterm delivery is not needed.165) However, if the 
mother is hemodynamically unstable or has severe HF, emergency delivery must be 
considered regardless of gestational age. A team consisting of a cardiologist, obstetrician, 
anesthesiologist, intensivist, and neonatologist would need to carefully evaluate the case 
and discuss the delivery timing. If the mother is hemodynamically unstable or requires 
mechanical assistance, a cesarean section must be considered. The use of spinal or epidural 
anesthesia for cesarean section is advised.165)
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1.  An angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker should not be used in 
women with peripartum cardiomyopathy prior to childbirth (class of recommendation III, level of 
evidence C).
2.  Limited treatment options are available for peripartum cardiomyopathy; bromocriptine can be 
considered if needed (class of recommendation IIb, level of evidence C).
3.  Subsequent pregnancy is not recommended in women diagnosed with peripartum 
cardiomyopathy and a left ventricular ejection fraction <25% or non-normalized left ventricular 
ejection fraction after treatment (class of recommendation III, level of evidence C).
The prognosis of peripartum cardiomyopathy usually depends on the recovery of ventricular 
contractility, which improves within 6 months after the symptom onset in 30–50% 
of patients and such patients have good long-term prognosis. However, if ventricular 
contractility does not improve, peripartum cardiomyopathy has a prognosis similar to that of 
dilated cardiomyopathy.166) Moreover, women with a history of peripartum cardiomyopathy 
who experience another pregnancy may die if ventricular function deteriorates; however, 
if ventricular contractility is normalized, subsequent pregnancy would not be fatal.167) If 
ventricular function continues to deteriorate, there is a high risk of venous thrombosis and 
thus anticoagulant therapy is advised. However, during pregnancy, heparin or low-molecular-
weight heparin must be considered due to the embryotoxicity of warfarin.
CONCLUSION
In this part of guideline, the management strategies according to the etiologies or co-
morbidities in AHF patients were discussed. Although the general principles of management 
follow the recommendations of the guidelines for AHF, it is important to identify the 
etiologies and accompanying disease as there are special considerations for each specific 
etiology. Various circumstances should be taken into account and appropriate management 
plan should be established for each patient.
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